23andMe (ME) Stock Price, News & Analysis

Company Overview

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $3.56 to $3.86
• 50-Day Range: $2.83 to $7.77
• 52-Week Range: $2.65 to $20.40
• Volume: 321,743 shs
• Average Volume: 477,761 shs
• Market Capitalization: $94.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.40
• Consensus Rating: Reduce

23andMe Stock Analysis - MarketRank™

23andMe scored higher than 43% of companies evaluated by MarketBeat, and ranked 736th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

23andMe has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

23andMe has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of 23andMe is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 23andMe is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

23andMe has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.12% of the float of 23andMe has been sold short.

Short Interest Ratio / Days to Cover

23andMe has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 23andMe has recently decreased by 5.00%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

23andMe does not currently pay a dividend.

Dividend Growth

23andMe does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.12% of the float of 23andMe has been sold short.

Short Interest Ratio / Days to Cover

23andMe has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 23andMe has recently decreased by 5.00%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.51

News Sentiment

23andMe has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for 23andMe this week, compared to 8 articles on an average week.

Search Interest

9 people have searched for ME on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, 23andMe insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.32% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 36.10% of the stock of 23andMe is held by institutions.

ME Stock Analysis - Frequently Asked Questions

How have ME shares performed this year?

23andMe's stock was trading at $18.27 at the start of the year. Since then, ME stock has decreased by 80.3% and is now trading at $3.6050.
View the best growth stocks for 2024 here.

How were 23andMe's earnings last quarter?

23andMe Holding Co. (NASDAQ:ME) released its earnings results on Tuesday, November, 12th. The company reported ($2.32) earnings per share for the quarter. The business earned $44.07 million during the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative trailing twelve-month return on equity of 129.98% and a negative net margin of 318.39%.

When did 23andMe's stock split?

23andMe's stock reverse split on the morning of Wednesday, October 16th 2024. The 1-20 reverse split was announced on Friday, October 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are 23andMe's major shareholders?

Top institutional shareholders of 23andMe include Geode Capital Management LLC (17.32%), GSA Capital Partners LLP (9.45%), FMR LLC (4.05%) and Jane Street Group LLC (2.96%). Insiders that own company stock include Kathy L Hibbs, William G Richards and Kenneth J Hillan.
View institutional ownership trends.

How do I buy shares of 23andMe?

Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of 23andMe own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 23andMe investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/03/2024
• Next Earnings (Estimated): 2/05/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ME
• CUSIP: N/A
• CIK: 1804591
• Web: vgacquisition.com
• Phone: 650-938-6300
• Fax: N/A
• Employees: 770
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.40
• High Stock Price Target: $9.40
• Low Stock Price Target: $9.40
• Potential Upside/Downside: +160.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($25.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-666,700,000.00
• Net Margins: -318.39%
• Pretax Margin: -318.39%
• Return on Equity: -129.98%
• Return on Assets: -62.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.24
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: $219.64 million
• Price / Sales: 0.43
• Cash Flow: $3.00 per share
• Price / Cash Flow: 1.20
• Book Value: $7.69 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 26,120,000
• Free Float: 19,244,000
• Market Cap: $94.16 million
• Optionable: Not Optionable
• Beta: 1.16